Publications in collaboration with researchers from Harvard University (10)

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2009

  1. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

    CLINICAL LYMPHOMA & MYELOMA

  2. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA

  3. Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

    CLINICAL LYMPHOMA & MYELOMA

  4. Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma

    CLINICAL LYMPHOMA & MYELOMA

  5. Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

    CLINICAL LYMPHOMA & MYELOMA

  6. VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

    CLINICAL LYMPHOMA & MYELOMA

  7. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

    CLINICAL LYMPHOMA & MYELOMA

2003

  1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group

    British Journal of Haematology, Vol. 121, Núm. 5, pp. 749-757